News argenx SE

Equities

ARGX

NL0010832176

Real-time Euronext Bruxelles Other stock markets 08:42:11 2024-04-25 am EDT			5-day change	1st Jan Change
348.7 ^EUR	-0.34%		+1.96%	+1.51%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	Apr. 16	PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease	Apr. 16	GL
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	Apr. 16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey	Mar. 28	AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	Mar. 27	PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024	Mar. 27	PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease	Mar. 27	GL
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	Mar. 27	CI
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024	Mar. 26	GL
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	Mar. 26	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	Mar. 26	MT
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	GL
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	Mar. 21	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	Mar. 08	PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting	Mar. 07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News argenx SE

Equities

ARGX

NL0010832176

Summary

Filters